Neurology Medical News about Migraine Disorders topiramate Drug Toxicity

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Topiramate-Induced Intractable Cough During Migraine Prophylaxis
Headache: The Journal of Head and Face Pain, 09/16/09

Maggioni F et al. – Topiramate is a highly effective drug in migraine prophylaxis and is considered a first–line treatment. The evidence for the efficacy of topiramate is based upon the results of several large, randomized, double–blind, placebo–controlled trials. Adverse events (AEs) are common and require discontinuation of the treatment in about 20–25% of patients, but they are rarely severe. There are reviews regarding topiramate–related AEs representing a large number of patients treated in controlled trials. The most common AEs are weight loss, dizziness, somnolence, abnormal thinking, fatigue, ataxia, confusion, paresthesias, impaired concentration, nervousness, amnesia, and language difficulties. The development of cough has never been reported as an AE during topiramate prophylaxis for migraine. The authors present 3 cases in which the prophylactic treatment for migraine with topiramate was discontinued due to the onset of primary intractable coughing.

<< Previous
Malignant middle cerebral artery infarction: clinical...

Next >>
A reassessment of risks and benefits of dopamine agonists in...